Strides Shasun Receives USFDA Nod For Promethazine Hydrochloride Tablets


Strides Shasun on Monday announced that it has received approval from the USFDA for Promethazine Hydrochloride tablets USP, 12.5 Mg, 25 mg and 50 mg.

According to the IMS data, the US market for Promethazine Hydrochloride tablets USP 12.5 mg, 25 mg and 50 mg is approximately USD 17 million. The product will be manufactured at the company flagship facility in Bangalore and marketed by Strides Pharma Inc. in the US market.

The tablets are used to prevent and treat nausea and vomiting related to the certain condition. It is also used to treat allergy symptoms such as rash, itching and runny nose.

The stock of Strides Shasun on Friday ended at Rs 998 per share lower by Rs 2.55 per share or 0.25% on the NSE. It has delivered negative returns of 11% and has underperformed the BSE Mid-cap and BSE Healthcare indices in a period of one year.

For Quick Trial – 8962000225 ✔
or mail us here: info@ways2capital.com
or visit http://www.ways2capital.co
✆ - 0731-6626222 | Toll Free - 1800-3010-2007 ✔
Give a Missed Call for Free Trial - 09699997717 ✔
Share on Google Plus

About Suhani Varma

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.

0 comments: